DO-BO

Are Primary Research Platforms Defining a New Era, Shrutya Bhalla?

In the latest episode of the MAP – Market Access Podcast, Dr. Stefan Walzer speaks with pricing and access expert Shrutya Bhalla about how primary research must evolve in an era of AI, policy shocks, and accelerating market complexity. The key takeaway: high‑quality primary research is no longer just about collecting insights – it must enable real strategic choices on pricing, access, launch sequencing, and evidence generation. This means moving from slow, static projects to continuous, platform‑driven, AI‑supported research, using AI for speed, automation and better hypotheses while keeping humans firmly in the lead for judgment, context and responsibility, and building research that is robust enough for MFN, new US tariffs, and fast‑changing global policy environments.

Shrutya also shares how new stakeholder research platforms like Mulya, and innovations such as Market Access 4.0 tools like mAxInsights, DO-Bo, Q-Bo and Wafle, are redefining how we run payer research: faster, more economical, and closer to real‑time decision needs. If you work in market access, pricing, Health Economics and Outcomes Research (HEOR) or commercialization, this episode is a must‑listen to understand where primary research is headed.

Related

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now. They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a […]

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, […]

From Olympic ice to AI-powered leadership: What can Market Access teams learn from elite sports? In the 111+1 anniversary episode of MAP – the Market Access Podcast, Dr. Stefan Walzer interviews Livia Altmann, a former Swiss Olympic ice hockey player who has transitioned into a leadership and “Human Intelligence 2.0” expert. Together, they explore how […]